Acura Shares Plummet After FDA Panel Rejects Pain Drug Acurox
WASHINGTON – Shares of Acura Pharmaceuticals Inc. fell 32 percent Friday after an FDA advisory panel a day earlier refused to back approval of the firm’s investigational pain drug Acurox (oxycodone HCl and niacin).

Read more on BioWorld